Cargando…
Implementation strategies to scale up self-administered depot medroxyprogesterone acetate subcutaneous injectable contraception: a scoping review
BACKGROUND: Self-administered depot medroxyprogesterone acetate subcutaneous injectable contraception (DMPA-SC) is registered in many countries. It shows great potential for improving contraceptive access, continuation, and autonomy. However, there are challenges in rolling out this new efficacious...
Autores principales: | Aderoba, Adeniyi Kolade, Steyn, Petrus Schoken, Kiarie, James Njogu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10318699/ https://www.ncbi.nlm.nih.gov/pubmed/37403147 http://dx.doi.org/10.1186/s13643-023-02216-2 |
Ejemplares similares
-
A prospective cohort study of the feasibility and acceptability of depot medroxyprogesterone acetate administered subcutaneously through self-injection()()()
por: Cover, Jane, et al.
Publicado: (2017) -
Ovulation suppression following subcutaneous administration of depot medroxyprogesterone acetate
por: Taylor, Douglas J., et al.
Publicado: (2022) -
An implementation project to expand access to self-administered depot medroxyprogesterone acetate (DMPA)()()
por: Katz, Micah, et al.
Publicado: (2020) -
Implementation strategies, facilitators, and barriers to scaling up and sustaining task-sharing in family planning: a protocol for a mixed-methods systematic review
por: Aderoba, Adeniyi Kolade, et al.
Publicado: (2023) -
Update to U.S. Selected Practice Recommendations for Contraceptive Use: Self-Administration of Subcutaneous Depot Medroxyprogesterone Acetate
por: Curtis, Kathryn M., et al.
Publicado: (2021)